In summary, GLP-1RAs have the potential to inhibit neuroinflammation and promote nerve regeneration through the "Tregs-microglia-neuron/NPCs" axis: (1) GLP-1RAs directly and indirectly inhibit the activation of microglia, promote their M2 polarization, and secrete cytokines such as IL-4, IL-10, TGF - , IL-2 to exert anti-inflammatory effects (100)
This may not cover everything about particular health conditions, medicines, generic alternatives, all possible side effects, drug interactions, warnings, alerts, lab tests, etc
But this is experimental territory with zero clinical data supporting the approach
These include labeling, claims, manufacturing, and documentation
The SAFE Drugs Act, introduced in December 2025, would expand the FDA's power over compounded and unregulated GLP-1 products and the telehealth companies that prescribe them (Dykema analysis)